Form 4: Arcutis Biotherapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 2,465 shares of common stock on February 28, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.
Summary
- On February 28, 2024, Todd Franklin Watanabe, the President and CEO of Arcutis Biotherapeutics, sold 2,465 shares of Arcutis Biotherapeutics, Inc. common stock at a price of $10.6 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units granted on February 27, 2020.
- Following the transaction, Watanabe directly owns 889,436 shares of common stock.
- Watanabe also has indirect ownership through several trusts and an LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't convey any particularly positive or negative sentiment about the company's prospects.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with vesting restricted stock units. It is a common practice and doesn't necessarily reflect a negative outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 02/27/2020 | Date of grant for the Restricted Stock Units that triggered the tax withholding obligation. |
| 02/28/2024 | Date of the stock sale transaction. |
| 03/01/2024 | Date of signature for the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.